Drugs / SCH 697243
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials | ||||||
| Phase 3 | NCT02676765 | Jun 2016 → Jan 2018 | — | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 3 | NCT01385371 | Jun 2011 → Aug 2012 | allergic rhinitis, conjunctivitis | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 3 | NCT00562159 | Nov 2007 → Sep 2009 | allergic disease, conjunctivitis, rhinitis | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 3 | NCT00550550 | Nov 2007 → Sep 2009 | allergic rhinitis, conjunctivitis | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02394600 | Apr 2015 → Apr 2016 | allergic disease | Queen's University | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-04-14 | ALK-Abelló A/S | ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK® (GRAZAX®) alk.net ↗ |
| 2014-02-03 | ALK-Abelló A/S | ALK's partner for North America, Merck, announces launch of GRASTEK® (GRAZAX®) in Canada alk.net ↗ |
| 2013-12-12 | ALK-Abelló A/S | FDA Advisory Committee meeting unanimously recommends approval of GRASTEK (GRAZAX®) alk.net ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCH 697243 | “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243)...” NCT01385371 ↗ |
| Known as | Grastek | “Grastek” NCT02676765 ↗ |
| Modality | Other / unclassified | “grass allergy immunotherapy tablet (AIT) treatment” PMID 21211643 ↗ Jan 2011 |
| Route | Other | “Grass sublingual tablet, once daily” NCT00550550 ↗ |